Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-18
    E.g., 2018-11-18

Articles

26924 items
9:36 AM, Oct 26, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Oyster Point's OC-01 dry eye nasal spray meets in Phase IIb

Oyster Point Pharma Inc. (Princeton, N.J.) said all three doses of OC-01 met the primary endpoint of improving tear production in the Phase IIb ONSET trial to treat dry eye disease. The company also reported...
12:34 PM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

BioLineRx reports response, survival data for BL-8040, Keytruda combo in pancreatic cancer

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from the Phase IIa COMBAT/KEYNOTE-202 trial showing that BL-8040 plus Keytruda pembrolizumab led to a disease control rate (DCR) of 34.5%, including one partial response and nine cases...
11:17 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Proteostasis' doublet CF therapy improves lung function in Phase I

Proteostasis Therapeutics Inc. (NASDAQ:PTI) reported that its doublet cystic fibrosis therapy improved percent predicted forced expiratory volume in 1 second (ppFEV1) and sweat chloride levels in a Phase I trial. The doublet therapy comprised CF...
11:13 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Keytruda, Inlyta combo headed for first-line RCC submissions

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab in combination with Inlyta axitinib met the primary endpoints vs. Sutent sunitinib in the Phase III KEYNOTE-426 trial as first-line treatment of renal cell carcinoma. Merck plans...
10:59 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Opdivo misses survival endpoint in Phase III for SCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said Opdivo nivolumab missed the primary endpoint of improving overall survival (OS) in the Phase III CheckMate -331 trial to treat small cell lung cancer in patients who relapsed following platinum-based...
10:38 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Eisai, Purdue insomnia candidate meets in second Phase III

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) said lemborexant met the primary and secondary endpoints in the Phase III SUNRISE 2 trial to treat insomnia. The trial is the second Phase III...
10:25 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Taris' TAR-302 reduces daily incontinence episodes by 75% in Phase Ib

Taris Biomedical LLC (Lexington, Mass.) reported Phase Ib data in August showing that TAR-302 reduced mean daily incontinence episodes by 75% at day 42 in idiopathic overactive bladder (OAB) patients who were experiencing an average...
10:21 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Celgene's Otezla meets in Phase III for scalp psoriasis

Celgene Corp. (NASDAQ:CELG) said Otezla apremilast met the primary endpoint in the Phase III STYLE trial to treat moderate to severe plaque psoriasis of the scalp. A significantly greater proportion of patients who received twice-daily...
10:17 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Novo's oral GLP-1 analog meets in Japanese Phase IIIa for Type II diabetes

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported that oral semaglutide met the primary safety endpoint in the Japanese Phase IIIa PIONEER 10 trial to treat Type II diabetes. The open-label trial evaluated once-daily 3, 7...
10:16 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Orphazyme seeking path forward for arimoclomol in NPC after Phase II/III miss

Orphazyme A/S (CSE:ORPHA) said arimoclomol missed the primary endpoints in a Phase II/III trial to treat Niemann-Pick disease type C (NPC). The company plans to meet with FDA and EMA to determine next steps for...

Pages